RE:RE:RE:FDA may fast track treatment after reviewI am not an expert in the area ...... A few comments on CT1812. CT1812 advantages: orally; small molecules so better penetrance to BBB; less cost to produce than antibody; one drug displaces all types of Abeta oligomers. PMN advantages: companion diagnostics; and, probably much better efficacy (CT1812 Y maze task P-value 0.013; PMN short term memory P-value <0.0001). actually, quite a few famous statisticians argued p value = 0.05 criteria being loose and arbitrary and propose 0.005(https://cos.io/blog/we-should-redefine-statistical-significance/). anyway, that's current fda golden standard. we'll hear more information after ctad meeting in boston, taking place nov. 14. actually,="" quite="" a="" few="" famous="" statisticians="" argued="" p="" value="0.05" criteria="" being="" loose="" and="" arbitrary="" and="" propose="" 0.005(https://cos.io/blog/we-should-redefine-statistical-significance/).="" anyway,="" that's="" current="" fda="" golden="" standard.="" we'll="" hear="" more="" information="" after="" ctad="" meeting="" in="" boston,="" taking="" place="" nov.="">